butane-2,3-dione | CAS:431-03-8

We serve butane-2,3-dione CAS:431-03-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
butane-2,3-dione

Chemical Name:butane-2,3-dione
CAS.NO:431-03-8
Synonyms:butane-2,3-dione
Dimethylglyoxal
2,3-Butanedione
2,3-Diketobutane
Biacetyl,Diacetyl
 
Physical and Chemical Properties:
Density 1.0±0.1 g/cm3
Boiling Point 88.0±0.0 °C at 760 mmHg
Melting Point -4–2 °C
Molecular Formula C4H6O2
Molecular Weight 86.089
Flash Point 7.2±0.0 °C
 
Specification:
Appearance:Yellow to yellow green clear liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Flavors and fragrances intermediate



Contact us for information like butane-2,3-dione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Biacetyl,Diacetyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,3-Butanedione Use and application,Dimethylglyoxal technical grade,usp/ep/jp grade.


Related News: Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.glutaric acid manufacturer Active Pharmaceutical Ingredients (APIs): Pharmaceutical active ingredients, which are the basic substances that constitute the pharmacological effects of pharmaceuticals, and are prepared by chemical synthesis, plant extraction, or biotechnology.5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole supplier The Transport Security Administration (TSA) will issue a new security directive to airlines from Sunday, according to a person briefed on the restrictions.Methyl 4-acetylbenzoate vendor Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.